Xvivo Perfusion ABXVIPF -1.32%91 PB Ratio is 3.92 as of Jun. 26, 2026, which is 36% below its 10-year median of 6.08. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 72.21% on this metric.
The historical rank and industry rank for Xvivo Perfusion AB's PB Ratio or its related term are showing as below:
XVIPF'
s PB Ratio Range Over the Past 10 Years
Min: 2.47 Med: 6.08 Max: 12.9
Current: 3.67
During the past 13 years, Xvivo Perfusion AB's highest PB Ratio was 12.90. The lowest was 2.47. And the median was 6.08.
XVIPF's PB Ratio is ranked worse than 72.21% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.02
vs XVIPF: 3.67
During the past 12 months, Xvivo Perfusion AB's average Book Value Per Share Growth Rate was 3.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 11.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 14.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 22.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Xvivo Perfusion AB was 39.50% per year. The lowest was 11.90% per year. And the median was 23.70% per year.
Back to Basics: PB Ratio
Xvivo Perfusion AB (OTCPK:XVIPF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Xvivo Perfusion AB PB Ratio Related Terms
Xvivo Perfusion AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Xvivo Perfusion AB (XVIPF) has a PB Ratio of 3.92 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Xvivo Perfusion AB and its competitors. This is 36% below median its historical median of 6.08. Over the past decade, Xvivo Perfusion AB's PB Ratio has ranged from 2.47 to 12.90. According to the industry distribution chart, Xvivo Perfusion AB ranks #569 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 72.2%.
Is Xvivo Perfusion AB's PB Ratio too high?
Xvivo Perfusion AB's current PB Ratio of 3.92 is 36% below median its 10-year median of 6.08. Over the past 10 years, this metric has ranged from a low of 2.47 to a high of 12.90. The Medical Devices & Instruments industry median PB Ratio is 2.02. Xvivo Perfusion AB's value of 3.92 is 94.1% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #569 out of 788 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #569 out of 788 companies for PB Ratio. This places Xvivo Perfusion AB in the lower half of its industry. The industry median PB Ratio is 2.02. Xvivo Perfusion AB's value of 3.92 is 94.1% above this benchmark. Historically, Xvivo Perfusion AB's own PB Ratio has ranged from 2.47 to 12.90 over the past decade. While the company's 10-year median is 6.08 vs. the industry median of 2.02, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current PB Ratio of 3.92 is 94.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current PB Ratio is 3.92, which is 36% below median its own 10-year median of 6.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current PB Ratio is 3.92, which is 36% below median its 10-year median of 6.08 and 94.1% above the Medical Devices & Instruments industry median of 2.02. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current PB Ratio is 3.92 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
PB Ratio: 3.92 (36% below median its 10-year median of 6.08)
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 94.1% above the Medical Devices & Instruments median (#569 of 788)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
